U.S. names HIV, arthritis drugs for next Medicare price talks [CNBC]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: CNBC
The U.S. government on Tuesday named the 15 new drugs targeted for Medicare price negotiations for 2028, including Gilead Sciences' HIV drug Biktarvy and Pfizer's arthritis treatment Xeljanz. It is the third round of drugs subject to former President Joe Biden's Inflation Reduction Act of 2022, which allowed the government to negotiate prices of some drugs purchased by the U.S. Medicare health program for people aged 65 and older or with disabilities. Despite the industry's longstanding opposition to the law and multiple failed lawsuits, the first negotiated prices on 10 drugs sold in pharmacies went into effect this year. The 2028 list also includes products that are administered in doctors' offices or hospitals, such as Novartis psoriasis drug Cosentyx and Botox, which is made by AbbVie. Other medications up for negotiation include Eli Lilly's GLP-1 diabetes drug Trulicity. “With prior rounds of pricing negotiations reasonable, and several of these medicines set to lose e
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at TD Cowen from $125.00 to $145.00. They now have a "buy" rating on the stock.MarketBeat
- Gilead Sciences (NASDAQ:GILD) had its price target raised by analysts at Wolfe Research from $150.00 to $155.00. They now have an "outperform" rating on the stock.MarketBeat
- Gilead's Trodelvy Win In TNBC Highlights Evolving Oncology Growth Story [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences (GILD) Is Up 11.0% After Trodelvy Combo Outperforms Keytruda Chemo In Phase 3 Trial - Has The Bull Case Changed? [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026Business Wire
GILD
Earnings
- 10/30/25 - Beat
GILD
Sec Filings
- 1/29/26 - Form 4
- 1/28/26 - Form 144
- 1/26/26 - Form 4
- GILD's page on the SEC website